seneste årsrapport - Sundhed.dk

12. DMSG publikationsliste:
2005
Andersen, NF.; Standal, T; Nielsen, JL; Heickendorff, L; Sørensen, FB; & Abildgaard, N. Syndecan-1 and
angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. British Journal
of Haematology, 2005; 128: 210-217.
Boissy, P; Andersen, TL; Abdallah, BM; Kassem, M; Plesner, T; Delaissé, JM. Resveratrol inhibits myeloma cell
growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res, 2005; 65: 9943-52.
Carlson, K; Hjorth, M; Knudsen, LM, for the Nordic Myeloma Study Group. Toxicity in standard melphalanprednisone
therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for
dose adjustment. British Journal of Haematology, 2005; 128: 631-5.
Hudlebusch HR, Theilgaard-Monch K, Lodahl M, Johnsen HE, Rasmussen T. Identification of ID-1 as a potential
target gene of MMSET in multiple myeloma. British Journal of Haematology. 130: 700-8. 2005.
Knudsen, LM; Nielsen, B; Gimsing, P; Geisler, C, Autologous stem cell transplantation in multiple myeloma:
Outcome in patients with renal failure. European Journal of Haematology, 2005; 74: 1-7.
2006
Bonhorst, J; Knudsen, LM; Rasmusssen, T; Moen, SH; Fløttum, M; Sundan, A; Espevik, T, Proliferation and
survival in multiple myeloma cells due to Toll-like receptor expression. Leukemia 2006; 20: 1138-44.
Chabanova, E; Johnsen, HE; Knudsen, LM; Larsen, L; Løgager, V; Yingru, S. Magnetic resonance investigation of
bone marrow following priming and stem cell mobilization. Magnetic Resonance in Medicine 2006; 24: 1364-70.
Gregersen, H; Jensen, P; Gislum, M; Jørgensen, B; Sørensen, HT; Nørgaard, M. Fracture risk in patients with
monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2006: 135; 62-67.
Lenhoff, S; Hjorth, M; Westin, J; Brinch, L: Bäckström, B: Carlson, K; Christiansen, I; Dahl, IM; Gimsing, P;
Hammerström, J; Johnsen, HE; Juliusson, G; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Tangen, JM;
Turesson, I; for the Nordic Myeloma Study Group. The impact of age on survival after intensive therapy for multiple
myeloma: a population-based study by the Nordic Myeloma Study Group. British Journal of Haematology, 2006;
133: 389-96.
Lenhoff, S; Hjorth, M; Turesson, I; Westin, J; Gimsing, P; Wislöff, F; Ahlberg, L; Carlson, K; Christiansen, I; Dahl,
IM; Forsberg, K; Brinch, L; Hammerström, J; Johnsen, HE; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I;
Nielsen, JL; Nordic Myeloma Study Group. Intensive therapy for multiple myeloma in patients younger than 60
years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after
transplantation. Haematologica, 2006; 91: 1228-33.
Mylin, AK; Rasmussen, T; Johansen, TS; Knudsen, LM; Nørgaard, PH; Lenhoff, S; Dahl, IM; and Johnsen; HE for
the Nordic Myeloma Study Group. Serum YKL-40 concentration in newly diagnosed multiple myeloma patients and
YKL-40 expression in malignant plasma cells. European Journal of Haematology, 2006; 77: 416-24.
Roer, O; Hammerstrøm, J; Lenhoff, S; Mylin, AK; Knudsen, LM; Rasmussen, T; and Johnsen, HE, for the Nordic
Myeloma Study Group. Quality assessment of autografting by probability evaluation: model estimation by clinical
end-points in newly diagnosed multiple myeloma patients. Cytotherapy, 2006; 8: 79-88.
Dansk Myelomatose Studie Gruppe side 58 Årsrapport 2011